Literature DB >> 15924242

Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy.

Hui Xing1, Shixuan Wang, Keqin Hu, Wenming Tao, Jing Li, Qinglai Gao, Xiaokui Yang, Danhui Weng, Yunpin Lu, Ding Ma.   

Abstract

PURPOSE: A low proliferating fraction in solid tumors limits the effectiveness of cell-cycle-dependent chemotherapeutic agents. To understand the molecular basis of such resistance, we examined the expression of the cyclin-dependent kinases inhibitor p27, and relationship with drug resistance and P-gp expression in ovarian cancer multicellular spheroids.
METHODS: We cultured ovarian cancer cells (A2780 and CAOV3) as multicellular spheroids and examined the expression of p27 and P-glycoprotein (P-gp) by western blot, flow cytometry and confocal. We also analyzed the cell-cycle distribution by flow cytometry. In addition, trypan blue exclusion testing and cell apoptosis analysis were used to detect the sensitivity to Taxol.
RESULTS: When transferred from monolayer to three-dimensional culture, a consistent upregulation of p27 protein and P-gp protein was observed in ovarian cancer cell lines. Compared with monolayer cells, there was a significant increase of G0-G1 phase cells and decrease of S and G2-M phase cells in spheroid cells. Aggregates of cells showed higher cell viability than monolayer cells. Antisense oligodeoxynucleotide (ASON) -mediated downregulation of p27 reduced intercellular adhesion, increased cell proliferation, downregulated P-gp expression and sensitized cells to Taxol.
CONCLUSIONS: Our results implicate that p27 serves as a regulator of drug resistance in ovarian tumors. ASON-mediated alteration of p27 reverses resistance of ovarian cancer to anticancer agents that are associated with increased sensitivity of ovarian cancer cells to chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15924242     DOI: 10.1007/s00432-005-0677-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  30 in total

1.  [Biological characteristics of multiple myeloma].

Authors:  J Dusek; V Scudla; Z Kolár; P Riháková; A Hlobilová
Journal:  Cesk Patol       Date:  2000-07

Review 2.  Roles of cyclin-dependent kinase inhibitors: lessons from knockout mice.

Authors:  H Kiyokawa; A Koff
Journal:  Curr Top Microbiol Immunol       Date:  1998       Impact factor: 4.291

3.  Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents.

Authors:  B St Croix; V A Flørenes; J W Rak; M Flanagan; N Bhattacharya; J M Slingerland; R S Kerbel
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

4.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

5.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

6.  Microenvironmental regulation of proliferation in multicellular spheroids is mediated through differential expression of cyclin-dependent kinase inhibitors.

Authors:  Karen E A LaRue; Mona Khalil; James P Freyer
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

7.  Alterations in the proliferating compartment of gastric mucosa during Helicobacter pylori infection: the putative role of epithelial cells expressing p27(kip1).

Authors:  Stavros Sougioultzis; Periklis G Foukas; Michalis Tzivras; Dimitrios Kourtessas; Vassilis G Gorgoulis; Panayiotis Davaris; Athanasios J Archimandritis
Journal:  Mod Pathol       Date:  2003-11       Impact factor: 7.842

Review 8.  Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer.

Authors:  Angel Alkarain; Joyce Slingerland
Journal:  Breast Cancer Res       Date:  2003-10-21       Impact factor: 6.466

9.  The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models.

Authors:  C Martin; J Walker; A Rothnie; R Callaghan
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

10.  Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence.

Authors:  K Jirström; A Ringberg; M Fernö; L Anagnostaki; G Landberg
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

View more
  15 in total

1.  Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer.

Authors:  Guang Chen; Na Yang; Xiang Wang; Si-Yuan Zheng; Yi Chen; Lin-Jiang Tong; Yi-Xue Li; Ling-Hua Meng; Jian Ding
Journal:  J Mol Med (Berl)       Date:  2010-05-28       Impact factor: 4.599

2.  Three-dimensional neuroblastoma cell culture: proteomic analysis between monolayer and multicellular tumor spheroids.

Authors:  Hari R Kumar; Xiaoling Zhong; Derek J Hoelz; Frederick J Rescorla; Robert J Hickey; Linda H Malkas; John A Sandoval
Journal:  Pediatr Surg Int       Date:  2008-09-17       Impact factor: 1.827

3.  Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.

Authors:  Rohann J M Correa; Yudith Ramos Valdes; Teresa M Peart; Elena N Fazio; Monique Bertrand; Jacob McGee; Michel Préfontaine; Akira Sugimoto; Gabriel E DiMattia; Trevor G Shepherd
Journal:  Carcinogenesis       Date:  2014-02-22       Impact factor: 4.944

4.  PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1.

Authors:  Shuo Yu; Yang Li; Hui Ren; Hong Zhou; Qian Ning; Xue Chen; Tinghua Hu; Lan Yang
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-21       Impact factor: 3.333

5.  Evaluating the influence of mechanical stress on anticancer treatments through a multiphase porous media model.

Authors:  Pietro Mascheroni; Daniela Boso; Luigi Preziosi; Bernhard A Schrefler
Journal:  J Theor Biol       Date:  2017-04-06       Impact factor: 2.691

6.  Small Molecule Targeting of Oxysterol-Binding Protein (OSBP)-Related Protein 4 and OSBP Inhibits Ovarian Cancer Cell Proliferation in Monolayer and Spheroid Cell Models.

Authors:  Ryan C Bensen; Gokhan Gunay; Matthew C Finneran; Isha Jhingan; Handan Acar; Anthony W G Burgett
Journal:  ACS Pharmacol Transl Sci       Date:  2021-02-04

Review 7.  Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis.

Authors:  Katharine L Sodek; K Joan Murphy; Theodore J Brown; Maurice J Ringuette
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

8.  Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids.

Authors:  Sylvain L'Espérance; Magdalena Bachvarova; Bernard Tetu; Anne-Marie Mes-Masson; Dimcho Bachvarov
Journal:  BMC Genomics       Date:  2008-02-26       Impact factor: 3.969

9.  Beclin-1 expression is retained in high-grade serous ovarian cancer yet is not essential for autophagy induction in vitro.

Authors:  Rohann J M Correa; Yudith Ramos Valdes; Trevor G Shepherd; Gabriel E DiMattia
Journal:  J Ovarian Res       Date:  2015-08-04       Impact factor: 4.234

10.  miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1.

Authors:  Chaoyang Sun; Na Li; Bo Zhou; Zongyuan Yang; Dong Ding; Danhui Weng; Li Meng; Shixuan Wang; Jianfeng Zhou; Ding Ma; Gang Chen
Journal:  Oncol Lett       Date:  2013-06-13       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.